TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.

Evolut Pro TAVR valve image courtesy of Medtronic. 

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR.